Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao
{"title":"氯喹和羟氯喹在SARS-Cov-2中的作用。重新利用旧药来对付今天的致命疾病","authors":"Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao","doi":"10.18231/j.jpbs.2020.001","DOIUrl":null,"url":null,"abstract":"Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19.\nMaterials and Methods: Here we present the database of trials with these compounds in COVID-19.\nDiscussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors.\nConclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable.\n\nKeywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Chloroquine and Hydroxychloroquine in SARS-Cov-2. Repurposing the old drugs against today’s deadly disease\",\"authors\":\"Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao\",\"doi\":\"10.18231/j.jpbs.2020.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19.\\nMaterials and Methods: Here we present the database of trials with these compounds in COVID-19.\\nDiscussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors.\\nConclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable.\\n\\nKeywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome\",\"PeriodicalId\":21014,\"journal\":{\"name\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.jpbs.2020.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research journal of pharmaceutical, biological and chemical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.jpbs.2020.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chloroquine and Hydroxychloroquine in SARS-Cov-2. Repurposing the old drugs against today’s deadly disease
Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19.
Materials and Methods: Here we present the database of trials with these compounds in COVID-19.
Discussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors.
Conclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable.
Keywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome